REPLIGEN CORP (RGEN) Stock Fundamental Analysis
USA - NASDAQ:RGEN - US7599161095 - Common Stock
149.06 USD
+4.49 (+3.11%)
149.06 USD
0 (0%)
Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 58 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
RGEN had a positive operating cash flow in the past year.
RGEN had positive earnings in 4 of the past 5 years.
RGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.48%, RGEN is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
RGEN has a Return On Equity of -0.67%. This is in the better half of the industry: RGEN outperforms 62.07% of its industry peers.
With a Return On Invested Capital value of 0.57%, RGEN perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 13.51%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROIC | 0.57% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN's Operating Margin of 3.72% is in line compared to the rest of the industry. RGEN outperforms 58.62% of its industry peers.
RGEN's Operating Margin has declined in the last couple of years.
RGEN's Gross Margin of 50.99% is in line compared to the rest of the industry. RGEN outperforms 56.90% of its industry peers.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for RGEN has been increased compared to 1 year ago.
The number of shares outstanding for RGEN has been increased compared to 5 years ago.
The debt/assets ratio for RGEN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.66 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN has a Altman-Z score of 6.66. This is amongst the best in the industry. RGEN outperforms 86.21% of its industry peers.
The Debt to FCF ratio of RGEN is 5.04, which is a neutral value as it means it would take RGEN, 5.04 years of fcf income to pay off all of its debts.
RGEN has a Debt to FCF ratio of 5.04. This is in the better half of the industry: RGEN outperforms 68.97% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
RGEN's Debt to Equity ratio of 0.26 is in line compared to the rest of the industry. RGEN outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 6.66 |
ROIC/WACC0.06
WACC10.18%
2.3 Liquidity
RGEN has a Current Ratio of 8.59. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 8.59, RGEN belongs to the best of the industry, outperforming 89.66% of the companies in the same industry.
A Quick Ratio of 7.32 indicates that RGEN has no problem at all paying its short term obligations.
RGEN has a Quick ratio of 7.32. This is amongst the best in the industry. RGEN outperforms 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
The Revenue has decreased by -8.54% in the past year.
Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.62% on average per year.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.96% yearly.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.18% yearly.
EPS Next Y16.09%
EPS Next 2Y22.84%
EPS Next 3Y24.46%
EPS Next 5Y25.96%
Revenue Next Year14.56%
Revenue Next 2Y14.07%
Revenue Next 3Y14.38%
Revenue Next 5Y16.18%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 89.80 indicates a quite expensive valuation of RGEN.
Compared to the rest of the industry, the Price/Earnings ratio of RGEN is on the same level as its industry peers.
RGEN is valuated expensively when we compare the Price/Earnings ratio to 26.10, which is the current average of the S&P500 Index.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 66.74.
RGEN's Price/Forward Earnings ratio is in line with the industry average.
RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 22.52, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 89.8 | ||
| Fwd PE | 66.74 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA ratio is in line with the industry average.
RGEN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 79.15 | ||
| EV/EBITDA | 79.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 24.46% in the coming years.
PEG (NY)5.58
PEG (5Y)12.64
EPS Next 2Y22.84%
EPS Next 3Y24.46%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
149.06
+4.49 (+3.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.43%
Inst Owner Change0.52%
Ins Owners0.5%
Ins Owner Change-2.37%
Market Cap8.39B
Revenue(TTM)707.89M
Net Income(TTM)-13827000
Analysts80.74
Price Target181.69 (21.89%)
Short Float %6.44%
Short Ratio3.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.95%
Min EPS beat(2)-6.83%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)8.75%
Min EPS beat(4)-6.83%
Max EPS beat(4)25.89%
EPS beat(8)4
Avg EPS beat(8)7.57%
EPS beat(12)8
Avg EPS beat(12)8.61%
EPS beat(16)12
Avg EPS beat(16)12.23%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)1.23%
Max Revenue beat(2)2.15%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)2
Avg Revenue beat(8)-0.75%
Revenue beat(12)3
Avg Revenue beat(12)-0.94%
Revenue beat(16)7
Avg Revenue beat(16)0.86%
PT rev (1m)-0.8%
PT rev (3m)-1.65%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)4.98%
EPS NY rev (1m)0.16%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)3.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 89.8 | ||
| Fwd PE | 66.74 | ||
| P/S | 12.44 | ||
| P/FCF | 79.15 | ||
| P/OCF | 63.48 | ||
| P/B | 4.07 | ||
| P/tB | 15.49 | ||
| EV/EBITDA | 79.69 |
EPS(TTM)1.66
EY1.11%
EPS(NY)2.23
Fwd EY1.5%
FCF(TTM)1.88
FCFY1.26%
OCF(TTM)2.35
OCFY1.58%
SpS11.98
BVpS36.65
TBVpS9.63
PEG (NY)5.58
PEG (5Y)12.64
Graham Number37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROCE | 0.9% | ||
| ROIC | 0.57% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 2.86% | ||
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% | ||
| FCFM | 15.72% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score4
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 5.34 | ||
| Cap/Depr | 34.97% | ||
| Cap/Sales | 3.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 | ||
| Altman-Z | 6.66 |
F-Score4
WACC10.18%
ROIC/WACC0.06
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y16.09%
EPS Next 2Y22.84%
EPS Next 3Y24.46%
EPS Next 5Y25.96%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year14.56%
Revenue Next 2Y14.07%
Revenue Next 3Y14.38%
Revenue Next 5Y16.18%
EBIT growth 1Y451.21%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year75.45%
EBIT Next 3Y40.62%
EBIT Next 5Y37.1%
FCF growth 1Y10.02%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-11.28%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 89.8 and the Price/Book (PB) ratio is 4.07.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 16.09% in the next year.